Boston, MA 08/08/2014 (wallstreetpr) – Medical technology firm, Medtronic, Inc. (NYSE:MDT) disclosed that the Food and Drug Administration or the FDA had given its nod for its Attain Performa quadripolar lead, and the Viva Quad S and Viva Quad XT cardiac resynchronization treatment defibrillators or CRT-D. The company expects to make available the devices in mid-September in the U.S.
The company said that quadripolar leads with four electrodes would lend a helping hand to the physicians to maximize cardiac resynchronization treatment delivery. The clinical challenges were addressed by the Attain Performa leads, which will be able to compromise lead position, thus providing physicians, who want to implant, with more choices to sustain its lead position and maximize CRT treatment.
Medtronic, Inc. (NYSE:MDT) indicated that its latest system provides additional pacing configurations compared to the conventional leads helping the physicians with more options for the betterment of patient care. In the same way, the narrow-spaced bipole assists to avoid phrenic nerve capture.
The latest quadripolar lead of Attain Performa cuts the phrenic nerve stimulation or PNS incidence because of a possible side effect resulting in muscle twitching, shortness of breath, and hiccups. Similarly, the Viva Quad XT gadget has come up with AdaptivCRT feature that protects normal heart rhythms apart from adjusting automatically to the patients’ requirements to customize treatment. It also includes VectorExpress skill that cuts down the timing of lead program to just two minutes by offering physicians with information of clinically actionable to help select the best pacing configurations for every patient.
Medtronic, Inc. (NYSE:MDT)’s vice president David Steinhaus said that the company would continue to make efforts to improve the healthcare of heart failure patients as in the past. With the latest addition of devices, the company is providing the heart failure patients with a top-notch system, he added.
Despite the FDA approval news, shares of Medtronic, Inc. (NYSE:MDT) shed 0.49% during the normal trading session on Thursday.